Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma
EBioMedicine, ISSN: 2352-3964, Vol: 48, Page: 178-190
2019
- 60Citations
- 75Captures
- 6Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations60
- Citation Indexes60
- 60
- CrossRef20
- Captures75
- Readers75
- 75
- Mentions6
- News Mentions6
- News6
Most Recent News
Single-Cell Level Variability May Help Predict Responses to BRAF Inhibitors in Melanoma
New targeted therapy options, such as BRAF and MEK inhibitors, offer advanced treatment for patients with melanoma; however, genetic variability often means that patients will
Article Description
Melanoma is a heterogeneous tumour, but the impact of this heterogeneity upon therapeutic response is not well understood. Single cell mRNA analysis was used to define the transcriptional heterogeneity of melanoma and its dynamic response to BRAF inhibitor therapy and treatment holidays. Discrete transcriptional states were defined in cell lines and melanoma patient specimens that predicted initial sensitivity to BRAF inhibition and the potential for effective re-challenge following resistance. A mathematical model was developed to maintain competition between the drug-sensitive and resistant states, which was validated in vivo. Our analyses showed melanoma cell lines and patient specimens to be composed of >3 transcriptionally distinct states. The cell state composition was dynamically regulated in response to BRAF inhibitor therapy and drug holidays. Transcriptional state composition predicted for therapy response. The differences in fitness between the different transcriptional states were leveraged to develop a mathematical model that optimized therapy schedules to retain the drug sensitive population. In vivo validation demonstrated that the personalized adaptive dosing schedules outperformed continuous or fixed intermittent BRAF inhibitor schedules. Our study provides the first evidence that transcriptional heterogeneity at the single cell level predicts for initial BRAF inhibitor sensitivity. We further demonstrate that manipulating transcriptional heterogeneity through personalized adaptive therapy schedules can delay the time to resistance. This work was funded by the National Institutes of Health. The funder played no role in assembly of the manuscript.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S2352396419306279; http://dx.doi.org/10.1016/j.ebiom.2019.09.023; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85073010725&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/31594749; https://linkinghub.elsevier.com/retrieve/pii/S2352396419306279; https://dx.doi.org/10.1016/j.ebiom.2019.09.023; https://www.ebiomedicine.com/article/S2352-3964(19)30627-9/fulltext?utm_campaign=EBM%20-%20Editor%27s%20Choice%20-%20Social&utm_content=104562327&utm_medium=social&utm_source=twitter&hss_channel=tw-2550149892; http://www.thelancet.com/article/S2352396419306279/abstract; http://www.thelancet.com/article/S2352396419306279/fulltext; http://www.thelancet.com/article/S2352396419306279/pdf; https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(19)30627-9/abstract; https://www.ebiomedicine.com/article/S2352-3964(19)30627-9/fulltext?utm_campaign=EBM%20-%20Editor%27s%20Choice%20-%20Social&utm_content=104562329&utm_medium=social&utm_source=twitter&hss_channel=tw-2550149892; https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(19)30627-9/fulltext; https://www.ebiomedicine.com/article/S2352-3964(19)30627-9/fulltext?utm_campaign=EBM%20-%20Editor%27s%20Choice%20-%20Social&utm_content=104562326&utm_medium=social&utm_source=twitter&hss_channel=tw-2550149892; https://www.ebiomedicine.com/article/S2352-3964(19)30627-9/fulltext; https://www.ebiomedicine.com/article/S2352-3964(19)30627-9/abstract#.XZpZIcgn3sE.twitter; https://www.ebiomedicine.com/article/S2352-3964(19)30627-9/fulltext?utm_campaign=EBM%20-%20Editor%27s%20Choice%20-%20Social&utm_content=104562328&utm_medium=social&utm_source=twitter&hss_channel=tw-2550149892
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know